Leucofeligen FeLV/RCP
Active substance
ATC code
Species
Cats.
Indications
For active immunisation of cats from eight weeks of age against:
- feline calicivirosis to reduce clinical signs,
- feline viral rhinotracheitis to reduce clinical signs and viral excretion,
- feline panleucopenia to prevent leucopenia and to reduce clinical signs,
- feline leukaemia to prevent persistent viraemia and clinical signs of the related disease.
Onset of immunity:
- 3 weeks after the first injection of primary vaccination for the calicivirus component - 3 weeks after the primary vaccination for the panleucopenia and leukaemia components, - 4 weeks after the primary vaccination for the rhinotracheitis virus component.
Duration of immunity:
After the primary vaccination course, the duration of immunity lasts for one year for all components.
Following a first booster vaccination one year after the primary vaccination course, a duration of immunity of 3 years has been demonstrated for the leukaemia component.
Dose to be administered and administration route
Subcutaneous use.
Reconstitute one dose of lyophilisate with one dose of suspension, shake gently and administer immediately.
Administer subcutaneously one dose (1ml) of the veterinary medicinal product according to the following regimen of vaccination.
Primary vaccination:
- first injection in kittens from 8 weeks of age - second injection 3 or 4 weeks later.
Maternally derived antibodies, especially those against feline panleucopenia virus, can negatively influence the immune response to vaccination. In such cases where maternally derived antibodies are expected, a third injection may be appropriate from 15 weeks of age.
Re-vaccinations:
Following a first booster vaccination one year after the primary vaccination course, subsequent vaccinations can be performed at intervals of three years for the leukaemia component. In this case, since annual revaccination is required for calicivirus, rhinotracheitis virus and panleucopenia virus components, a single dose of FELIGEN RCP can be used annually.
The vaccine can be used as a booster for kittens or cats previously vaccinated with FELIGEN RCP and LEUCOGEN separately.
Adverse reactions
Cats:
Common (1 to 10 animals / 100 animals treated): | Injection site reaction1, Injection site swelling1, Injection site oedema1, Injection site nodule1. Hyperthermia2,3, Apathy3 Digestive tract disorder3. |
Rare (1 to 10 animals / 10,000 animals treated): | Injection site pain4, 5, Sneezing5, Conjunctivitis5. |
Very rare (<1 animal / 10,000 animals treated, including isolated reports): | Anaphylaxis6. Febrile limping syndrome reactions7. |
1A moderate and transient local reaction (<2 cm) is observed after the first injection and resolves spontaneously within 3 to 4 weeks at the most. After the second injection, and subsequent administrations, this reaction is markedly reduced.
2Lasting 1 to 4 days.
3Transient signs.
4At palpation.
5This resolves without any treatment.
6In case of anaphylactic shock, appropriate symptomatic treatment should be administered.
7May occur very rarely in kittens, as reported in the literature after the use of any vaccine containing a Feline Calicivirus component.
Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or its local representative or the national competent authority via the national reporting system. See the package leaflet for respective contact details.
